Europace最新文献

{"title":"Ventricular pulsed field ablation from bench to bedside: preclinical and clinical evidence from a systematic review and meta-analysis.","authors":"Paolo Compagnucci, Luca Finori, Michela Casella, Alessio Gasperetti, Henry D Huang, Yari Valeri, Leonardo D'Angelo, Francesca Campanelli, Giorgio Giacomini, Giovanni Volpato, Laura Cipolletta, Quintino Parisi, Luigi Di Biase, Andrea Natale, Pasquale Santangeli, Antonio Dello Russo","doi":"10.1093/europace/euag221","DOIUrl":"10.1093/europace/euag221","url":null,"abstract":"<p><strong>Aims: </strong>Evidence supporting the use of pulsed field ablation (PFA) for ventricular arrhythmia (VA) ablation remains limited and heterogeneous, and the relationship between preclinical lesion characteristics and clinical outcomes is incompletely defined. We sought to systematically summarize preclinical lesion metrics and clinical outcomes of ventricular PFA.</p><p><strong>Methods and results: </strong>We performed a systematic review and meta-analysis of preclinical and clinical studies of ventricular PFA. Preclinical studies reporting lesion depth or transmurality and clinical studies detailing procedural efficacy and safety were included. Random-effects models were used to pool lesion characteristics and clinical outcomes. Seventy-five studies were included (33 preclinical, 43 clinical; 355 patients). In preclinical models, mean lesion depth was 5.96 mm(95%CI, 5.07-6.84) in healthy endocardium and 5.19 mm (95%CI, 2.58-7.79) in healthy epicardium. Notably, lesion depth was quantitatively similar in models of scarred myocardium (5.96 mm; 95%CI, 5.39-6.53). Lesion transmurality was variable in healthy tissues (32%; 95%CI, 15-52%) but higher within scar (53%; 95%CI, 36-70%). Consistently, lesion depth was similar between PFA and RF in healthy myocardium, but greater with PFA in scarred models (within-study mean depth difference, 2.09 mm; 95%CI, 0.84-3.34). Greater contact force, repeated applications, and higher energy/duration settings were associated with increased lesion depth. Clinically, acute success was high for both premature ventricular complexes (PVCs,90%; 95%CI, 83-96%) and ventricular tachycardia (VT;92%; 95%CI, 87-96%) in studies with ≥3patients. Over a mean follow-up of approximately 5months, recurrence rates were 19% (95%CI, 12-28%) for PVCs and 21% (95%CI, 10-35%) for VT. The overall complication rate was 10% (95%CI, 5-17%) in studies with ≥3patients, with coronary artery spasm and conduction disturbances representing the most frequent adverse events.</p><p><strong>Conclusion: </strong>Ventricular PFA demonstrates high acute efficacy and encouraging mid-term outcomes, supported by preclinical evidence of favourable lesion penetration within scarred myocardium. Safety considerations-particularly coronary and conduction system effects-and the heterogeneity of preclinical evidence highlight the need for further investigation.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":10.2,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13574506/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148789932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Late arrhythmias following Fontan completion: insights from a Korean Multicentre Fontan Registry of over 1000 extracardiac conduit surgeries.","authors":"Ja-Kyoung Yoon, Kyung-Jin Ahn, Soo-Jin Kim, Chang-Ha Lee, I Seok Kang, Jinyoung Song, June Huh, Sang-Yun Lee, Mi Kyoung Song, Seung Min Baek, Jae-Suk Baek, Seul Gi Cha, Chun Soo Park, Eun Seok Choi, Hoon Ko, Se Yong Jung, Joowon Lee, Jae Young Lee, Yeo Hyang Kim, Young-Seok Lee, Eun-Jung Bae","doi":"10.1093/europace/euag123","DOIUrl":"10.1093/europace/euag123","url":null,"abstract":"<p><strong>Aims: </strong>Awareness of long-term arrhythmia complications after Fontan surgery is increasing, but the impact of surgical type and risk factors on arrhythmia development remain incompletely understood.</p><p><strong>Methods and results: </strong>We retrospectively analysed 1492 Fontan patients from the Korean multicentre registry (1979-2019), categorized into atriopulmonary connection (AP) (n = 106), lateral tunnel (LT) (n = 234), and extracardiac conduit (ECC) (n = 1143) with a median follow-up of 14 years. Arrhythmias occurred in 13.3% of patients at a median age of 17.3 years (tachyarrhythmias 9.9%, bradyarrhythmias 6.8%). At 20 years, freedom from any arrhythmia, tachyarrhythmia, and bradyarrhythmia was 82.5%, 86.9%, and 90.5%, respectively. On multivariable analysis, AP (HR 5.89, 95% CI 3.75-9.25; P < 0.001) and LT (HR 2.85, 95% CI 1.93-4.21; P < 0.001) were associated with a higher risk of arrhythmia compared with ECC. Older age at Fontan surgery also independently increased arrhythmia risk (HR 1.06, 95% CI 1.03-1.10; P < 0.001). Compared with ECC Fontan, LT Fontan and AP Fontan were associated with a progressively higher risk of both tachyarrhythmias (HR 2.99 and 8.20, respectively) and bradyarrhythmias (HR 2.63 and 5.47, respectively; all P < 0.001). The all-cause mortality rate and Fontan failure rate were 9.3% (0.69 per 100 patient-years) and 20.0% (1.61 per 100 patient-years), respectively. Late-onset arrhythmias were associated with an increased risk of mortality and Fontan failure (P = 0.003 and P < 0.001).</p><p><strong>Conclusion: </strong>This large, long-term registry shows that ECC Fontan confers a lower arrhythmia risk than LT or AP, and arrhythmias serve as a marker of Fontan failure and mortality in post-Fontan patients.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":"28 9","pages":""},"PeriodicalIF":10.2,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13571843/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148963234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Upgrade procedures of pacemakers or implantable cardioverter-defibrillators require creative clinical decision making and careful planning that begins at the first implantation.","authors":"Alexander H Maass, Hessel F Groenveld, Michiel Rienstra","doi":"10.1093/europace/euag174","DOIUrl":"10.1093/europace/euag174","url":null,"abstract":"","PeriodicalId":11981,"journal":{"name":"Europace","volume":"28 9","pages":""},"PeriodicalIF":10.2,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13611650/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149037190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practical guide on the use of the PulseSelect pulsed field ablation system for atrial fibrillation ablation procedures.","authors":"Jason G Andrade, Lucas V A Boersma, Melanie A Gunawardene, Nitesh Sood, Devi Nair, Atul Verma, Laurent Macle, Stavros Mountantonakis","doi":"10.1093/europace/euag227","DOIUrl":"10.1093/europace/euag227","url":null,"abstract":"<p><p>Pulsed field ablation (PFA), which employs intermittent short-duration high-voltage electrical impulses to induce cellular membrane pore formation, is one of the most substantial innovations in the field of cardiac electrophysiology. In contrast to thermal ablation using radiofrequency or cryoenergy, PFA is theoretically capable of preferential tissue destruction, avoiding the negative effects of thermal energy and minimizing the risk of collateral damage. The optimal use of PFA requires operators to adapt their procedural approach to the novel catheter and energy source. The purpose of this manuscript is to summarize the best practice procedural considerations related to PFA with the PulseSelect ablation catheter, within the context of the contemporary evidence-base and with a focus on a predominantly fluoroscopy-based workflow. A foundational approach to pulmonary vein isolation with the PulseSelect catheter would reduce procedural heterogeneity, ultimately improving patient outcomes through the adoption of standardized evidence-based practices.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":10.2,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13595252/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148818106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cryoballoon ablation vs. antiarrhythmic drug therapy as initial treatment for persistent atrial fibrillation: the multicentre randomized CEPAF trial.","authors":"Tianyou Ling, Yazhou Lin, Yangyang Bao, Lin Chen, Wei Xu, Baopeng Tang, Jing Xu, Jingquan Zhong, Wei Li, Zhongbao Ruan, Qi Lu, Suxia Guo, Jingfeng Wang, Bing Han, Kai Tang, Tong Liu, Rui Zeng, Jiangui He, Hong Zhi, Changjian Lin, Yue Wei, Zhijun Wu, Ning Zhang, Qi Jin, Yu Yu, Liqun Wu","doi":"10.1093/europace/euag230","DOIUrl":"10.1093/europace/euag230","url":null,"abstract":"<p><strong>Aims: </strong>Evidence supporting first-line cryoballoon ablation (CBA) in treatment-naive persistent atrial fibrillation (PersAF) is limited. Consequently, we compared CBA with guideline-directed antiarrhythmic drug (AAD) therapy in this advanced form of disease.</p><p><strong>Methods and results: </strong>This multicentre, prospective, randomized, open-label trial assigned 320 symptomatic, treatment-naive patients with PersAF (1:1) to CBA or AAD therapy. The primary endpoint was the first documented atrial tachyarrhythmia recurrence lasting at least 30 s during days 91-365. Secondary endpoints included recurrence during days 1-90 and 1-365, time-to-first recurrence, quality of life, and safety. In the intention-to-treat population, recurrence during days 91-365 occurred in 30/160 (18.8%) patients assigned to CBA and 71/160 (44.4%) assigned to AAD therapy (absolute difference, -25.6 percentage points; 95% confidence interval, -35.4 to -15.8; P < 0.001). Supportive time-to-event analysis favoured CBA (hazard ratio for AAD vs. CBA, 2.29; 95% confidence interval, 1.48-3.56; log-rank P < 0.001). In CBA vs. AAD comparisons, overall recurrence during days 1-365 was 23.8% vs. 55.6%, and early recurrence was 11.2% vs. 28.1% (both P < 0.001; respectively). Improvement in AFEQT score was greater with CBA (17.3 vs. 6.6 points; P < 0.001), whereas SF-12 component scores did not differ significantly. Adverse events recorded on event forms were infrequent in both cohorts.</p><p><strong>Conclusion: </strong>In selected treatment-naive patients with PersAF, first-line CBA reduced atrial tachyarrhythmia recurrence and improved disease-specific quality of life compared with AAD therapy.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov, NCT04942834.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":10.2,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13582022/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148863848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circadian rest-activity rhythm disruption and ventricular arrhythmias in implantable cardioverter-defibrillator patients: a prospective wearable study.","authors":"Femke D Raijmakers, Diana My Frodi, Joss Langford, Hanno L Tan, Tariq O Andersen, Samuel Ruipérez-Campillo, Peter Karl Jacobsen, Niels Risum, Søren Zöga Diederichsen, Reinoud E Knops, Jesper Hastrup Svendsen, Maarten Z H Kolk, Fleur V Y Tjong","doi":"10.1093/europace/euag216","DOIUrl":"10.1093/europace/euag216","url":null,"abstract":"","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":10.2,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13537319/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148789920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DENND3-p.R534S disrupts dyadic microdomain architecture to drive potentially pro-arrhythmic calcium and electrophysiologic instability.","authors":"Shan Gao, Changsung John Kim, Dan Ye, David J Tester, John R Giudicessi, Michael J Ackerman","doi":"10.1093/europace/euag193","DOIUrl":"10.1093/europace/euag193","url":null,"abstract":"<p><strong>Aims: </strong>Inherited ventricular arrhythmias (VAs) frequently occur in the absence of pathogenic variants in canonical ion channel genes, suggesting alternative mechanisms of electrical instability. DENND3 is a guanine nucleotide exchange factor that regulates Rab GTPase-mediated trafficking, but its role in cardiac excitation-contraction coupling and membrane microdomain organization remains undefined.</p><p><strong>Methods and results: </strong>We studied induced pluripotent stem cell-derived cardiomyocytes generated from a CRISPR/CAS9-engineered ultra-rare DENND3-p.R534S variant-inserted line (previously identified in an idiopathic ventricular fibrillation pedigree) and matched isogenic controls. Multielectrode array recordings, live-cell calcium imaging, super-resolution imaging using expansion microscopy, and biochemical analyses were used to assess electrical activity, calcium handling, membrane architecture, and calcium release unit organization. Potentially therapeutic studies were performed using genetic and pharmacologic inhibition of Rab11b. DENND3-p.R534S induced pluripotent stem cell-derived cardiomyocytes exhibited multicellular electrical instability characterized by increased beat-to-beat variability, arrhythmic activity, conduction slowing, and prolonged excitation-contraction delay. These abnormalities were accompanied by heterogeneous and dyssynchronous calcium cycling despite preserved expression of major calcium-handling proteins. Super-resolution imaging revealed disruption of BIN1-dependent membrane architecture and nanoscale uncoupling of Cav1.2 and RyR2. Inhibition of Rab11b restored BIN1 organization, re-established dyadic coupling, normalized calcium cycling, and improved electrical stability.</p><p><strong>Conclusion: </strong>These findings support a model in which altered trafficking balance contributes to disruption of membrane microdomain organization, leading to dyadic uncoupling, calcium instability, and electrical dysfunction. Modulation of the Rab11b-mediated trafficking pathway restored structural and functional abnormalities, supporting the trafficking-associated pathway as a potential therapeutic target in DENND3-associated ventricular arrhythmia.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":10.2,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13554801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148812076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Effectiveness of a Novel Dual-Energy Radiofrequency/Pulsed Field Ablation Catheter: 12 Month Results of the FlexPulse Study.","authors":"Ayman A Hussein, Gediminas Rackauskas, Sri Sundaram, Jonathan P Piccini, Franz Xaver Roithinger, Patricia Tung, Jose Osorio, B Judson Colley, Usman R Siddiqui, Dhanunjaya R Lakkireddy, Larry A Chinitz, Matthew C Hyman, Laura Zitella Verbick, Nick Dirckx, Virginia Woods, Monica Lo","doi":"10.1093/europace/euag238","DOIUrl":"https://doi.org/10.1093/europace/euag238","url":null,"abstract":"<p><strong>Background and aims: </strong>Pulsed field (PF) ablation is increasingly used to treat paroxysmal atrial fibrillation (PAF). FlexPulse (NCT06676072) was conducted to evaluate safety and effectiveness of a novel dual-energy, flexible-tip focal ablation catheter with radiofrequency and PF for treatment of symptomatic, drug-refractory PAF.</p><p><strong>Methods: </strong>FlexPulse was a global, prospective, single arm, multicentre study. The ablation procedures targeted pulmonary vein isolation (PVI) and adjunctive ablation at operators' discretion. The primary safety endpoint was occurrence of pre-defined safety events within 7-days of any ablation procedure. The primary effectiveness endpoint was freedom from a composite of recurrent AF/atrial tachycardia/atrial flutter, repeat procedure, new use or escalation of class I/III AAD, and/or cardioversion through 12-months.</p><p><strong>Results: </strong>Overall, 180 subjects underwent PAF ablation. Successful PVI was achieved in all participants. Additional non-PV ablations were performed in 37.2% (67/180) of subjects. The primary safety endpoint event rate was 1.7%. The primary effectiveness endpoint was 74.6% at 12-months, and freedom from documented AF/AFL/AT recurrence was 77.4% (92.6% without weekly transtelephonic monitoring). In 15 subjects who underwent repeat ablation after the blanking period, remapping indicated that 79.7% (47/59) of the PVs were durably isolated from the index procedures. Retrospective analysis found that workflows with PFA Index (PI) ≥30 and AutoMark distance up to 6 mm target had a 12-month freedom from AF/AFL/AT of 84.6%.</p><p><strong>Conclusions: </strong>In this trial, ablation with TactiFlex Duo in patients with symptomatic, drug-refractory PAF was safe and effective.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":10.2,"publicationDate":"2026-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Multi-Omics to Mechanism: Nucleocapsid-RCHY1-JUNB Axis Underlies SARS-CoV-2 Related Atrial Fibrillation Vulnerability.","authors":"Chengyu Xiang, Yeqian Zhu, Wei Zhao, Pengcheng Zhao, Yan Hua, Ruijie Xu, Youfu Huang, Albrecht Von Brunn, Dingguo Zhang, Fengxiang Zhang","doi":"10.1093/europace/euag207","DOIUrl":"10.1093/europace/euag207","url":null,"abstract":"<p><strong>Background and aims: </strong>SARS-CoV-2 exposure has been linked to cardiovascular complications, including atrial fibrillation (AF), but the host pathways coupling viral factors to atrial remodeling and AF vulnerability remain incompletely understood.</p><p><strong>Methods: </strong>We integrated multi-cohort human transcriptomes from SARS-CoV-2-infected cardiac models and AF tissues, applied WGCNA and machine-learning-based feature selection, and profiled immune infiltration. To approximate a sustained low-grade inflammatory milieu relevant to prolonged COVID-19-related cardiovascular sequelae, mice with cardiac SARS-CoV-2 N expression underwent repeated low-dose LPS administration. JUNB loss-of-function was evaluated by rAAV9-mediated cardiac knockdown, with echocardiographic, electrophysiological, histological, and molecular phenotyping. Mechanistic studies were performed in modified cardiomyocytes.</p><p><strong>Results: </strong>Integrated transcriptomic analyses identified JUNB as a shared hub associated with SARS-CoV-2-related cardiac signaling and AF, with enrichment of inflammatory pathways relevant to atrial remodeling. In the chronic inflammatory model, cardiac N expression exacerbated atrial enlargement, inflammatory-fibrotic remodeling, AF inducibility and duration, and AERP shortening, whereas cardiac JUNB knockdown attenuated these changes. Mechanistically, co-immunoprecipitation and in-cell ubiquitination assays showed that SARS-CoV-2 N enhanced the JUNB-RCHY1 interaction, promoting K63-linked ubiquitination and stabilizing JUNB. Site-mapping and functional assays identified K36 as the dominant ubiquitination site required for N-driven JUNB stabilization, TNF-α/NF-κB activation, and downstream inflammatory and fibrotic gene programs.</p><p><strong>Conclusion: </strong>Cardiac SARS-CoV-2 N protein promotes atrial inflammatory-fibrotic remodeling and AF vulnerability under chronic inflammatory conditions relevant to post-acute or prolonged COVID-19-related cardiovascular sequelae through RCHY1-dependent ubiquitination and stabilization of JUNB, identifying the N-RCHY1-JUNB axis as a mechanistically defined pathway for future therapeutic investigation.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":10.2,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148720636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Repeat catheter ablation vs. direct current cardioversion for recurrent atrial fibrillation after prior ablation: a propensity-matched analysis.","authors":"Michel Abou Khalil, Mohammad Montaser Atasi, Yara Menassa, Maximilian Moersdorf, Christian M Massad, Alex El Darzi, Carlo El Khoury, Yishi Jia, Ghassan Bidaoui, Hadi Younes, Joe Abi-Rached, William Herbst, Charles Campbell, Eli Tsakiris, Abboud Hasan, Yingshuo Liu, Rodolfo Montiel Quintero, Omar Kreidieh, Amitabh C Pandey, Han Feng, Qussay Marashly, Nassir F Marrouche","doi":"10.1093/europace/euag199","DOIUrl":"10.1093/europace/euag199","url":null,"abstract":"","PeriodicalId":11981,"journal":{"name":"Europace","volume":"28 8","pages":""},"PeriodicalIF":10.2,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13526514/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148863912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}